In: Finance
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.50 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.7 million packages a year. Cash costs of production in the first year are expected to be $4.25 per package in real terms for the headache-only brand. Production costs are expected to be $4.80 in real terms for the headache and arthritis pill. All prices and costs are expected to rise at the general inflation rate of 2 percent.
Either product requires further investment. The headache-only pill could be produced using equipment costing $27 million. That equipment would last three years and have no resale value. The machinery required to produce the broader remedy would cost $30 million and last three years. The firm expects that equipment to have a $1,100,000 resale value (in real terms) at the end of Year 3.
The firm uses straight-line depreciation and has a tax rate of 23 percent. The appropriate real discount rate is 8 percent.
a.Calculate the NPV for headache pain reliever only. (Do not round intermediate calculations and enter your answer in dollars, not millions of dollars, rounded to 2 decimal places, e.g., 1,234,567.89.)
b.Calculate the NPV for headache and arthritis pain reliever. (Do not round intermediate calculations and enter your answer in dollars, not millions of dollars, rounded to 2 decimal places, e.g., 1,234,567.89.)
Solution:
a)Calculation of NPV of headache pain reliever
i)Annual Depreciation=Cost of Equipment/life
=$27/3=$9 million
ii)Statement showing after tax cash inflows for each year
Year | 1($ in million) | 2($ in million) | 3($ in million) |
[email protected] | 25.50 | 25.50 | 25.50 |
Less:[email protected] | 12.75 | 12.75 | 12.75 |
Net Revenue | 12.75 | 12.75 | 12.75 |
Add:Inflation @2% | 0.255 | 0.5151 | |
Total Revenue | 12.75 | 13.005 | 13.2651 |
Less:Depreciation | 9.00 | 9.00 | 9.00 |
EBT | 3.75 | 4.005 | 4.2651 |
Less:tax @23% | 0.8625 | 0.92115 | 0.9810 |
EAT | 2.8875 | 3.08385 | 3.2841 |
Add:Depreciation | 9 | 9 | 9 |
After tax cash inflows | 11.8875 | 12.08385 | 12.2841 |
iii)Present value of cash inflows using discount rate of 8%
=11.8875/(1+.08)^1+12.08385/(1+.08)^2+12.2841/(1+.08)^3
=$31.1184128 million
iv)NPV=Present value of cash inflows-Initial Investment
=$31.1184128 million-$27 million
=$4.1184128million
Thus NPV for headache pain reliever is 4,118,412.78